XTL Biopharmaceuticals Ltd. XTLB
NASDAQ
| 12/31/2025 | 12/31/2023 | ||||
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 0.00% | -9.07% | |||
| Total Receivables | -- | -- | |||
| Inventory | -- | -- | |||
| Prepaid Expenses | -- | -62.34% | |||
| Finance Division Loans and Leases Current | -- | -- | |||
| Total Finance Division Other Current Assets | -- | -- | |||
| Other Current Assets | 0.00% | -- | |||
| Total Current Assets | 0.00% | -10.38% | |||
|
|
|||||
| Total Current Assets | 0.00% | -10.38% | |||
| Net Property, Plant & Equipment | -- | -- | |||
| Long-term Investments | -- | -- | |||
| Goodwill | -- | -- | |||
| Total Other Intangibles | -- | 0.00% | |||
| Finance Div Loans & Leases LT | -- | -- | |||
| Total Finance Div Other LT Assets | -- | -- | |||
| Total Other Assets | -- | -- | |||
| Total Assets | 0.00% | -8.90% | |||
|
|
|||||
| Total Accounts Payable | 0.00% | -99.38% | |||
| Total Accrued Expenses | 0.00% | -- | |||
| Short-term Debt | -- | -- | |||
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | |||
| Finance Division Debt Current | -- | -- | |||
| Total Finance Division Other Current Liabilities | 0.00% | -- | |||
| Total Other Current Liabilities | 0.00% | -- | |||
| Total Current Liabilities | 0.00% | 27.16% | |||
|
|
|||||
| Total Current Liabilities | 0.00% | 27.16% | |||
| Long-Term Debt | -- | -- | |||
| Short-term Debt | -- | -- | |||
| Capital Leases | -- | -- | |||
| Finance Division Debt Non Current | -- | -- | |||
| Total Finance Division Other Non Current Liabilities | -- | -- | |||
| Total Other Liabilities | -- | -- | |||
| Total Liabilities | 0.00% | 27.16% | |||
|
|
|||||
| Common Stock & APIC | 0.00% | 0.00% | |||
| Retained Earnings | 0.00% | -0.18% | |||
| Treasury Stock & Other | 0.00% | 0.00% | |||
| Total Common Equity | 0.00% | -11.24% | |||
|
|
|||||
| Preferred Stock Redeemable | -- | -- | |||
| Preferred Stock Non Redeemable | -- | -- | |||
| Preferred Stock Convertible | -- | -- | |||
| Preferred Stock, Others | -- | -- | |||
| Total Preferred Equity | -- | -- | |||
|
|
|||||
| Total Common Equity | 0.00% | -11.24% | |||
| Total Preferred Equity | -- | -- | |||
| Total Minority Interest | -- | -- | |||
| Total Equity | 0.00% | -11.24% | |||
|
|
|||||